Navigation Links
DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial
Date:7/24/2014

d Mr. Bacha.

Clinical Trial Update

Our lead drug candidate, VAL-083, is currently undergoing a Phase I/II clinical trial in the United States as a potential new therapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. 

We most recently provided an update at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) where it was disclosed that VAL-083 was safe and well tolerated at doses up to 30mg/m2 and that the next cohort (40mg/m2) had been opened for enrollment. DelMar's ASCO data presentation can be viewed on our website at: http://www.delmarpharma.com/products/publications/.

We are now pleased to confirm that the 40mg/m2 cohort is fully enrolled and, subject to completion of a safety review period, we plan to move forward with amending the protocol to allow us to treat patients at higher dosing levels. 

"To date, we have not seen evidence of a dose limiting toxicity in the initial patients at the 40mg/m2 dose. We believe it is prudent to pursue higher dosing levels with the goal of obtaining the maximum the level of drug that can be safely delivered to patients. This will enhance our likelihood of success in achieving our goal to commercialize VAL-083 as a new medicine for the treatment of refractory GBM patients who currently have no available therapeutic options."

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain can
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
2. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
3. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
4. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
5. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
8. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
10. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... 2014 Epigenetics finds applications in a ... oncology, drug discovery, developmental biology, and research for metabolic ... of the most widely used techniques for the discovery ... prevalence of cancer is rapidly growing worldwide. In 2012, ... cancer deaths, and 32.6 million people living with cancer ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... new, injectable weight-loss drug has been approved by the ... Tuesday approved Saxenda (liraglutide) for adults who are obese ... least one weight-related health condition, such as high blood ... taking the drug, made by Novo Nordisk, should still ... noted. "Obesity is a public health concern and ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... Americans on Healthy Living and Eating, ROSEMONT, ... is partnering with the U.S. Department of Agriculture ... habits and make healthier,lifestyle choices as part of ... and End Childhood Obesity.", The USDA,s Center ...
... no longer just for doctors as PointOne ... WAUWATOSA, Wis., June 10 PointOne Systems, ... tool, known as,RedBox Technology, will begin providing reports ... dramatic change from the industry,s focus,on hospitals, research ...
... takes a toll on pros, study says , , TUESDAY, June ... hampers the performances of continent-crossing pro baseball players but may ... , An analysis of 10 years of pro baseball scores ... they were severely jet-lagged. The effect, however, wears off after ...
... 2008 Pregnant women can safely undergo essential dental ... to 21 weeks gestation, says a study published in ... American Dental Association . , Although obstetricians generally consider ... evidence has been lacking. To address this issue, researchers ...
... 10 As government,authorities reel from a record breaking ... a new book brings to light the science --,and ... being,promoted by the food and nuclear industries., Written ... of Food is timely and fact-filled. The book details ...
... DALLAS, June 10 BeaconEquity.com announces the,availability of TraderNotes ... can view all of the daily trading notes for ... Lantis Laser Inc. (Pink Sheets: LLSR),Elbit Imaging Ltd. (Nasdaq: ... ),Ophthalmic Imaging Systems Inc. (OTC Bulletin Board: OISI), Alcon ...
Cached Medicine News:Health News:National Dairy Council Joins USDA in 'Partnering With MyPyramid' 2Health News:PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals 2Health News:Baseball Teams Strike Out When Jet-Lagged 2Health News:Baseball Teams Strike Out When Jet-Lagged 3Health News:Essential dental treatment safe for pregnant women, says ADA journal study 2Health News:New Book Reveals Decades-Long Food Safety PR Scam 2Health News:BeaconEquity.com Issues TraderNotes on Medical Instruments and Supplies Stocks: LLSR, EMITF, BLTI, OISI, ACL, LMNX, MELA, PMII 2Health News:BeaconEquity.com Issues TraderNotes on Medical Instruments and Supplies Stocks: LLSR, EMITF, BLTI, OISI, ACL, LMNX, MELA, PMII 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: